Jaguar health announces submission of investigational new drug (ind) application to fda for drug candidate for the symptomatic relief of diarrhea from cholera

Jaguar is concentrating financial and management resources on two near-term late-stage clinical events san francisco, ca / accesswire / august 30, 2022 / jaguar health, inc. (nasdaq:jagx) ("jaguar" or the "company") today announced the submission by the company's wholly owned subsidiary, napo pharmaceuticals (napo), of an investigational new drug (ind) application to the u.s. food and drug administration for napo's np-300 drug product candidate for the symptomatic relief of diarrhea from cholera. "i am very pleased that we have submitted the ind to fda for the proposed cholera-related diarrhea indication for np-300," said steven king, phd, jaguar's chief sustainable supply, ethnobotanical research & ip officer.
JAGX Ratings Summary
JAGX Quant Ranking